#5

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 532232000900 DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (if known, see 37 CFR 1.5) **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** 10/531,545 INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PRIORITY DATE CLAIMED PCT/US03/33366 20 October 2003 18 October 2002 TITLE OF INVENTION PROCESSES FOR IDENTIFYING QUADRUPLEX-TARGETED ANTIVIRAL MOLECULES APPLICANT(S) FOR DO/EO/US Adam SIDDIQUI-JAIN Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. х This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must 3. include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. a. b. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. b have not been made; however, the time limit for making such amendments has NOT expired. C. have not been made and will not be made. d An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14 An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825 (1 17 х CDR) 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 19

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/531,545			INTERNATIONAL APPLICATION NO. PCT/US03/33366		ATTORNEY'S DOCKET NUMBER 532232000900		
20. x Other items or information: Response To Notice To Comply (10 pages) Statement to Support Filing and Submission (2 pages) Paper copy of Sequence Listing (2 pages) Copy of Notice to Comply (2 pages) Return Receipt Postcard					ages)		
The following fees have been submitted					CALCULATION	S PTO USEONLY	
21. Basic national fee (37 CFR 1.492(a))					\$		
22. Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)					\$		
23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)					\$		
	TOTAL OF 21, 22	and 23 =			\$ 0.0	0	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	Extra Sheets		n additional 50 or fraction up to a whole number)	RATE			
- 100 =	/50 =			x \$250.00	\$		
			e, examination fee, or the e (37 CFR 1.492(h)).	oath or declaration	\$		
CLAIMS	NUN	MBER FILED	NUMBER EXTRA	RATE			
Total clair		- 20 =		X			
Independent		- 3 =		<u> </u>			
MULTIPLE DEP	ENDENT CLAIM(S) (II applicable)	TOTAL OF A	BOVE CALCULATIONS =	\$ 0.0		
X Applicant	claims small entity	status See 37 (CFR 1.27. Fees above an		0.00		
				SUBTOTAL =	\$ 0.0	0	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$		
TOTAL NATIONAL FEE =				\$ 0.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$				
			т	OTAL FEES ENCLOSED =	\$	0.00	
					Amount to be refunded:	\$	
					Amount to be charged	\$ 0.00	

and the desired

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$ to c	cover the above fees is enclosed.				
b. Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed.	in the amount of \$ to cover the above fees.				
c. x The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-1952 Adupticate copy of this cheet is enclosed.					
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed an granted to restore the International Application to pending status.					
	Brenda Wallach				
SEND ALL CORRESPONDENCE TO:	SIGNATURE				
Brenda J. Wallach					
Morrison & Foerster LLP 12531 High Bluff Drive, Suite #100	Brenda J. Wallach				
San Diego, California 92130	NAME				
	45,193				
CUSTOMER NUMBER: 25225	REGISTRATION NUMBER				
COSTOWIER MOMBER. 20220					
•					
	·				
I hereby certify that this correspondence is being deposited w US, in an envelope addressed to: MS PCT, Commissioner for shown below.	rith the U.S. Postal Service as Express Mail, Airbill No. EV 783 104 053 or Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date				
Dated: December 13, 2005 Signature:	udy al (Judy Calem)				
	<u> </u>				

ATTY. DOCKET NO. 532232000900

661Q 7 2003 DEC 2005



U.S. APPLICATION NUMBER NO.

United States Patent and Trademark Office

MORRISON&FOERSTER

UNITED STATES DEPARTMENT OF COMME United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO. Box 1450 Alexandria, Vriginia 22313-1450 www.aspto.gov

10/531,545		-Lau	ric L-Hi	 -	
	Adam SID	D160	11 - JA	14	
25225 BJ MORRISON & FOERSTER LLP	DOCKETED: Sea	. [Sata	2_	
3811 VALLEY CENTRE DRIVE SUITE 500	DUE DATE:	2	24/	65	
SAN DIEGO, CA 92130-2332	FINAL DUE DATE:	E	24	06	,

PCT/US03/33366 I.A. FILING DATE PRIORITY DATE

INTERNATIONAL APPLICATION NO.

10/20/2003

10/18/2002

CONFIRMATION NO. 3896 371 FORMALITIES LETTER

OC000000017306242

Date Mailed: 10/24/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

FIRST NAMED APPLICANT

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

cc: Gare Haney 11/15/05

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

JOHN L ANDERSON

Telephone: (703) 308-9140 EXT 211

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.		
10/531,545	PCT/US03/33366	532232000900		

FORM PCT/DO/EO/922 (371 Formalities Notice)